Drug Target Review

AUGUST 28, 2024

We then incubate the cells to mature into ‘pro-regenerative’ macrophages and insert two RNA messages to produce two human proteins that will be expressed at the site of injury when these ‘engineered’ macrophages are given back to the patient.

Therapies 116

Therapies Disease Engineering Medical Schools 116

The Pharma Data

MARCH 8, 2021

Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. About Molnupiravir. Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment, and prevention of transmission, as well as SARS-CoV-1 and MERS.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

NOVEMBER 18, 2021

At the recommendation of the eDMC, Merck is stopping dosing in the trial, with continued monitoring of study participants. In light of the findings from the MK-8507-013 study, Merck conducted a review of trends in total lymphocyte and CD4+ T-cell counts in company-sponsored clinical trials of ISL across all indications and dosing regimens.

Clinical Trials 52

Clinical Trials Treatment Trials RNA 52

The Pharma Data

OCTOBER 25, 2021

At 48 weeks, both trials met their primary efficacity endpoint of chance of actors with HIV-1 RNA situations ? The safety and tolerability profile of DOR/ ISL during the trials to date are harmonious with the preliminarily reported Phase 2 studies. Merck Research Laboratories. “ PIFELTRO and DELSTRIGO.

Treatment 52

Treatment Trials RNA Clinical Trials 52

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials (MOVe-OUT and MOVe-IN) of molnupiravir (MK-4482/EIDD-2801), an investigational oral antiviral therapeutic. About Molnupiravir.

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories RNA 52

The Pharma Data

SEPTEMBER 1, 2021

Study Now Enrolling Participants Who Live in the Same Household as Someone With Symptomatic, Laboratory-Confirmed COVID-19. The global study is enrolling individuals who are at least 18 years of age and reside in the same household as someone with laboratory-confirmed SARS-CoV-2 infection with symptoms.

Laboratories 52

Laboratories Clinical Trials Virus Trials 52

Codon

APRIL 2, 2023

A giant dataset about the rat brain, and how neurons connect to each other, was collected and pooled together from 20 different research laboratories. Nucleic Acids Research. Read A new DNA polymerase variant, called RT-KTq I614Y, can directly detect RNA modifications, including pseudouridine (Ψ) and queuosine (Q).

DNA 52

DNA RNA Engineering Licensing 52